Biosynthesis and transbilayer flipping of mycobacterial PIM glycolipids

分枝杆菌 PIM 糖脂的生物合成和跨双层翻转

基本信息

  • 批准号:
    7632133
  • 负责人:
  • 金额:
    $ 20.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-15 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mycobacteria species, exemplified by M. tuberculosis and M. leprae are the cause of major diseases in humans. In this R21 `high risk/high impact' application we propose an exploratory program to define early steps in the biosynthesis of phosphatidylinositol mannosides (PIMs). PIMs are a family of mannolipids that plays a critical role in the pathogenesis of mycobacteria, because they are biosynthetic precursors in the assembly of the key cell surface glycoconjugates lipomannan (LM) and lipoarabinomannan (LAM). PIM biosynthesis occurs in the cytoplasmic membrane and there is considerable evidence to suggest that it occurs by the sequential addition of mannose residues to PI. We hypothesize that the first three mannosyltransfer reactions of PIM biosynthesis occur on the cytoplasmic face of the membrane and use GDP-mannose as the mannosyl donor; these reactions are catalyzed by the mannosyltransferases (ManTs) PimA, PimB and an undefined enzyme that we term PimC*. We further propose that subsequent mannosylation reactions use polyprenol-phosphate-mannose (PPM) as the mannosyl donor and occur on the membrane's periplasmic face. The enzyme that catalyzes the first of these periplasmically oriented reactions is unknown; we refer to it as PimD*. To accommodate the topological split in PIM biosynthesis, we propose that the trimannosylated glycolipid (AcPIM3) produced by PimC* must flip across the membrane in order to be further mannosylated. Since non-catalyzed phospholipid flipping is a rare event, we propose that AcPIM3 flipping requires a lipid translocator or flippase (referred to herein as Flp*), a protein that remains to be identified. The nexus of three steps surrounding the topological split in the PIM assembly pathway thus remains to be defined. In this "proof of principal" project evolving from close interactions between the three principal investigators over the last year, we propose two specific aims to identify the protein components required for these steps. Our studies will exploit the experimental model Mycobacterium smegmatis in conjunction with a multi-faceted approach including bioinformatics, mutational analysis, and biochemical reconstitution of transport activity. Our aims are: 1) To identify PimC* and PimD*, the ManTs that catalyze the mannosyltransfer reactions that occur immediately prior to and after the transbilayer translocation of a PIM intermediate. 2) To develop a reconstitution system that recapitulates Flp*-catalyzed PIM flip- flop and to use this system to identify Flp*, the flippase responsible for flipping AcPIM3 across the membrane. Thus the unifying theme of this proposal encompasses filling in `missing steps' in the biogenesis of PIMs, establish OUR hypothesized pathway, all in relation to identifying unique, extracellular targets. PUBLIC HEALTH RELEVANCE: Herein, two exploratory specific aims are proposed to address the vital missing gaps in the assembly of core glycolipids in Mycobacterium.
描述(由申请人提供):分枝杆菌属,例如M.结核和M.麻风病是人类主要疾病的病因。在这个R21“高风险/高影响”的应用程序中,我们提出了一个探索性的计划,以确定磷脂酰肌醇甘露糖苷(PIM)的生物合成的早期步骤。PIM是在分枝杆菌的发病机制中起关键作用的甘露糖脂家族,因为它们是关键细胞表面糖缀合物脂甘露聚糖(LM)和脂阿拉伯甘露聚糖(LAM)的组装中的生物合成前体。PIM生物合成发生在细胞质膜中,并且有相当多的证据表明它是通过将甘露糖残基顺序添加到PI上而发生的。我们假设PIM生物合成的前三个甘露糖基转移反应发生在膜的细胞质表面,并使用GDP-甘露糖作为甘露糖基供体;这些反应由甘露糖基转移酶(ManT)PimA、PimB和一种未定义的酶催化,我们称之为PimC*。我们进一步提出,随后的甘露糖基化反应使用聚戊烯醇-磷酸-甘露糖(PPM)作为甘露糖基供体,并发生在膜的周质面上。催化这些周质定向反应中的第一个的酶是未知的;我们将其称为PimD*。为了适应PIM生物合成中的拓扑分裂,我们提出由PimC* 产生的三甘露糖基化糖脂(AcPIM 3)必须翻转穿过膜以进一步甘露糖基化。由于非催化的磷脂翻转是一种罕见的事件,我们提出,AcPIM 3翻转需要一个脂质转运蛋白或翻转酶(在本文中称为Flp*),一种蛋白质,仍有待确定。因此,围绕PIM组装路径中的拓扑分裂的三个步骤的关系仍有待定义。在这个“主要证据”项目中,我们提出了两个具体目标,以确定这些步骤所需的蛋白质组分。我们的研究将利用实验模型耻垢分枝杆菌结合多方面的方法,包括生物信息学,突变分析,和生化重建的运输活动。我们的目标是:1)鉴定PimC* 和PimD*,即催化紧接在PIM中间体的跨双层易位之前和之后发生的甘露糖基转移反应的ManT。2)开发重现Flp* 催化的PIM翻转的重构系统,并使用该系统鉴定负责翻转AcPIM 3穿过膜的翻转酶Flp*。因此,该提案的统一主题包括填补PIM生物发生中的“缺失步骤”,建立我们假设的途径,所有这些都与识别独特的细胞外靶标有关。公共卫生关系:在此,提出了两个探索性的具体目标,以解决分枝杆菌核心糖脂组装中的重要缺失缺口。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DELPHI CHATTERJEE其他文献

DELPHI CHATTERJEE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DELPHI CHATTERJEE', 18)}}的其他基金

Validation of urine/serum LAM in HIV/nonHIV TB suspects and POC Test Development
HIV/非 HIV 结核病疑似者的尿液/血清 LAM 验证和 POC 测试开发
  • 批准号:
    10179309
  • 财政年份:
    2018
  • 资助金额:
    $ 20.43万
  • 项目类别:
Validation of urine/serum LAM in HIV/nonHIV TB suspects and POC Test Development
HIV/非 HIV 结核病疑似者的尿液/血清 LAM 验证和 POC 测试开发
  • 批准号:
    9925722
  • 财政年份:
    2018
  • 资助金额:
    $ 20.43万
  • 项目类别:
Biosynthesis and transbilayer flipping of mycobacterial PIM glycolipids
分枝杆菌 PIM 糖脂的生物合成和跨双层翻转
  • 批准号:
    7511622
  • 财政年份:
    2008
  • 资助金额:
    $ 20.43万
  • 项目类别:
Anti MDR-TB MICs and Cytotoxicity of New Compounds
新化合物的抗耐多药结核病 MIC 和细胞毒性
  • 批准号:
    6735405
  • 财政年份:
    2003
  • 资助金额:
    $ 20.43万
  • 项目类别:
M AVIUM WALL STRUCTURES FROM AIDS PATIENTS
来自艾滋病患者的 M AVIUM 墙结构
  • 批准号:
    2751059
  • 财政年份:
    1997
  • 资助金额:
    $ 20.43万
  • 项目类别:
M AVIUM WALL STRUCTURES FROM AIDS PATIENTS
来自艾滋病患者的 M AVIUM 墙结构
  • 批准号:
    2545040
  • 财政年份:
    1997
  • 资助金额:
    $ 20.43万
  • 项目类别:
M AVIUM WALL STRUCTURES FROM AIDS PATIENTS
来自艾滋病患者的 M AVIUM 墙结构
  • 批准号:
    6044167
  • 财政年份:
    1997
  • 资助金额:
    $ 20.43万
  • 项目类别:
Structure of LAM in Relation to Biology and Biosynthesis
LAM 结构与生物学和生物合成的关系
  • 批准号:
    6544799
  • 财政年份:
    1996
  • 资助金额:
    $ 20.43万
  • 项目类别:
STRUCTURE OF LAM IN RELATION TO BIOLOGY AND BIOSYNTHESIS
LAM 结构与生物学和生物合成的关系
  • 批准号:
    2672427
  • 财政年份:
    1996
  • 资助金额:
    $ 20.43万
  • 项目类别:
Structure of LAM in Relation to Biology and Biosynthesis
LAM 结构与生物学和生物合成的关系
  • 批准号:
    6850695
  • 财政年份:
    1996
  • 资助金额:
    $ 20.43万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.43万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了